Larimar Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Larimar Therapeutics has a total shareholder equity of $211.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $237.2M and $25.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$226.06m |
| Equity | US$211.40m |
| Total liabilities | US$25.76m |
| Total assets | US$237.16m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ZA71's short term assets ($231.1M) exceed its short term liabilities ($21.2M).
Long Term Liabilities: ZA71's short term assets ($231.1M) exceed its long term liabilities ($4.6M).
Debt to Equity History and Analysis
Debt Level: ZA71 is debt free.
Reducing Debt: ZA71 has no debt compared to 5 years ago when its debt to equity ratio was 4.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZA71 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ZA71 has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 4.8% each year.